Catalyst Pharmaceuticals (CN2) Stock Overview
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CN2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Catalyst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.22 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$16.15 |
| Beta | 0.68 |
| 1 Month Change | 0.90% |
| 3 Month Change | 8.62% |
| 1 Year Change | -0.54% |
| 3 Year Change | 16.07% |
| 5 Year Change | 615.63% |
| Change since IPO | 2,295.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| CN2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -1.0% | 0.7% |
| 1Y | -0.5% | -29.9% | 14.7% |
Return vs Industry: CN2 exceeded the German Biotechs industry which returned -31.1% over the past year.
Return vs Market: CN2 underperformed the German Market which returned 14.2% over the past year.
Price Volatility
| CN2 volatility | |
|---|---|
| CN2 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CN2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CN2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 181 | Rich Daly | catalystpharma.com |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Catalyst Pharmaceuticals, Inc. Fundamentals Summary
| CN2 fundamental statistics | |
|---|---|
| Market cap | €2.52b |
| Earnings (TTM) | €185.23m |
| Revenue (TTM) | €492.28m |
Is CN2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CN2 income statement (TTM) | |
|---|---|
| Revenue | US$578.20m |
| Cost of Revenue | US$97.52m |
| Gross Profit | US$480.67m |
| Other Expenses | US$263.11m |
| Earnings | US$217.56m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.77 |
| Gross Margin | 83.13% |
| Net Profit Margin | 37.63% |
| Debt/Equity Ratio | 0% |
How did CN2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 10:07 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Catalyst Pharmaceuticals, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Herrmann | Baird |
| Joel Beatty | Baird |
| null null | Baird |